Fig. 7.

Subcutaneous tumors established in NCR nu/nu nude mice. In-vivo antitumor efficacy of KKA was determined using an athymic mice xenograft model bearing HCT-116 tumors at day 21 post-inoculation. (A) Mice from the negative control (distilled water); (B) mice under treatment with KKA at 25mg/kg; (C) mice under treatment with KKA at 50 mg/kg; (D) mice under treatment with KKA at 100 mg/kg; (E) mice under treatment with capecitabine at10 mg/kg (positive control); (F) tumor morphology of the representative groups of animals (from left to right: (1) negative control; (2) 25 mg/kg of KKA; (3) 50 mg/kg of KKA; (4) 100 mg/kg of KKA; (5) 10 mg/kg of capecitabine. KKA, Potassium koetjapate.